Revvity (NYSE:RVTY) Stock Rating Upgraded by Wall Street Zen

Revvity (NYSE:RVTY) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

Several other equities research analysts have also recently weighed in on the company. Stifel Nicolaus decreased their price target on Revvity from $110.00 to $100.00 and set a “hold” rating on the stock in a research report on Wednesday, May 6th. Weiss Ratings upgraded shares of Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 30th. Evercore reaffirmed an “outperform” rating on shares of Revvity in a research note on Wednesday. The Goldman Sachs Group decreased their target price on shares of Revvity from $110.00 to $95.00 and set a “neutral” rating on the stock in a report on Tuesday, April 14th. Finally, Barclays raised their price target on shares of Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Three investment analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat.com, Revvity has an average rating of “Hold” and an average price target of $108.36.

Revvity Trading Up 0.1%

Shares of RVTY stock opened at $114.81 on Friday. The stock has a market capitalization of $12.81 billion, a price-to-earnings ratio of 54.67, a PEG ratio of 2.09 and a beta of 1.07. The company’s fifty day simple moving average is $108.01 and its two-hundred day simple moving average is $99.94. Revvity has a 1 year low of $81.22 and a 1 year high of $118.30. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.50.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. The firm had revenue of $711.00 million during the quarter, compared to analyst estimates of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The business’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same period last year, the company earned $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts anticipate that Revvity will post 5.35 earnings per share for the current year.

Institutional Investors Weigh In On Revvity

Hedge funds have recently added to or reduced their stakes in the company. KBC Group NV lifted its stake in Revvity by 115.4% in the fourth quarter. KBC Group NV now owns 39,522 shares of the company’s stock worth $3,824,000 after purchasing an additional 21,174 shares during the last quarter. Corient Private Wealth LLC grew its stake in shares of Revvity by 985.0% during the fourth quarter. Corient Private Wealth LLC now owns 126,568 shares of the company’s stock valued at $12,245,000 after buying an additional 114,903 shares during the last quarter. Diamond Hill Capital Management Inc. increased its holdings in shares of Revvity by 6.3% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 426,899 shares of the company’s stock worth $41,302,000 after buying an additional 25,233 shares during the period. California State Teachers Retirement System increased its holdings in shares of Revvity by 19.8% in the first quarter. California State Teachers Retirement System now owns 133,809 shares of the company’s stock worth $11,723,000 after buying an additional 22,075 shares during the period. Finally, Catalyst Funds Management Pty Ltd bought a new stake in shares of Revvity in the 4th quarter valued at about $1,596,000. Institutional investors own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.